Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Hair Loss Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SCUBE3 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SCUBE3 Recombinant Protein (ECD-Fc / His-Tag) HEK293 Expressed (Native Glycosylation), High Purity (>95%), Endotoxin Controlled, Sequence Verified. |
View SCUBE3 Products |
| Gene Delivery | SCUBE3 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and overexpression assays. |
View SCUBE3 Products |
| Benchmark Ab | Anti-SCUBE3 Recombinant Antibody High-affinity positive control for binding and neutralization assays. |
View SCUBE3 Products |
| Validator | SCUBE3 siRNA Set Target-specific knockdown verification in functional assays. |
View SCUBE3 Products |
| Related Target A | TGFBR1 Primary signaling receptor partner; SCUBE3 acts as a co-receptor to activate TGF-beta signaling. |
View TGFBR1 Products |
| Related Target B | EGFR SCUBE3 modulates EGFR signaling pathways, promoting tumor progression and metastasis. |
View EGFR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Glycosylation-Dependent Binding | HEK293 mammalian expression system ensures native post-translational modifications and proper folding of CUB and EGF-like domains. |
| Aggregation and Instability | Optimized formulation and high-purity (>95% by SDS-PAGE) recombinant proteins with verified theoretical molecular weight. |
| Lack of Controls | Sequence-verified benchmark antibodies and positive control reagents included in the portfolio. |
| False Positives | Highly specific siRNA sets available for target validation and knockdown verification. |
Live SCUBE3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of SCUBE3 (Signal peptide, CUB domain and EGF-like domain-containing protein 3) is emerging as a highly versatile frontier, spanning both oncology and regenerative medicine. Historically recognized as a promoter of epithelial-mesenchymal transition (EMT) and metastasis in non-small cell lung cancer (NSCLC) and breast cancer, recent breakthrough research has highlighted SCUBE3 as a critical signaling molecule secreted by dermal papilla cells to trigger hair follicle stem cell activation.
The race for SCUBE3 therapeutics is intensifying, with major players shifting focus from traditional mAbs in oncology to local recombinant protein therapies for androgenetic alopecia (hair loss). As first-generation therapies reach preclinical and early clinical stages, the next wave of R&D is targeting the precise modulation of SCUBE3-mediated TGF-beta and EGFR pathway activation, requiring highly characterized, glycosylated proteins to screen for functional agonists and antagonists.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Recombinant Protein (Agonist) | Amplifica Holdings, Academic Spin-offs | Androgenetic Alopecia (Hair Loss) | Native Glycosylation & Stability (Need HEK293-expressed, endotoxin-controlled SCUBE3) |
| Monoclonal Antibody (Antagonist) | Oncology-focused Biotechs | NSCLC, Breast Cancer, Osteosarcoma | Receptor Binding & Neutralization (Need high-purity ECD-Fc and TGFBR1/EGFR proteins) |
| Gene Therapy / mRNA | Dermatology Research Labs | Alopecia Areata | Expression Validation (Need Lentivirus/ORF for stable expression monitoring) |